# TriGemX Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/trigemx-bio

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.kallyope.com
- Total disclosed funding: $463M
- Latest round: Series D (Feb 15, 2022)
- Investors on record: 15

## About

TriGemX Bio, Inc., formerly known as Kallyope Inc. is a US-based biotechnology company specializing in therapeutic solutions for neurological and metabolic diseases, utilizing its unique Klarity™ platform for the development of innovative pharmaceuticals.Kallyope Inc. is dedicated to advancing therapeutic solutions for complex health issues. Founded in 2015 in New York, US, the company has engaged in 7 investment deals to date. The latest funding round occurred on May 11, 2023, when Kallyope secured USD 8.2 mn in Grant funding from the Bill & Melinda Gates Foundation Trust. Overall, the total amount raised by the company is USD 236.00 mn. The firm was established by a team with significant expertise in biotechnology and pharmaceuticals, though specific individual founder backgrounds are not detailed.Kallyope Inc. focuses on innovative therapeutic solutions for neurological and metabolic diseases, leveraging its proprietary Klarity™ platform. This platform integrates a diverse array of technologies to facilitate the identification and development of novel therapeutics aimed at addressing significant health challenges. The company's primary offerings are centered around discovering differentiated pharmaceuticals that target the underlying mechanisms of complex diseases. Kallyope serves a wide range of stakeholders in the healthcare ecosystem, including pharmaceutical companies, researchers, and healthcare providers, who benefit from the advancements in medication development. The company is engaged in research and development activities primarily within North America and Europe, where there is a growing demand for effective treatment options in the neurological and metabolic sectors.Kallyope's revenue structure is based on collaborations and partnerships with various entities in the pharmaceutical and biotechnology industries. The company enters into strategic alliances that may involve research funding, milestone payments, and royalties on future product sales. These collaborations facilitate the advancement of Kallyope's therapeutic candidates while providing a financial framework for ongoing research initiatives. While specific pricing plans and transaction structures are not disclosed, it is presumed that the business transactions involve B2B partnerships, focusing on joint development agreements and licensing arrangements with established firms in the healthcare sector. Kallyope's flagship offerings, developed through its Klarity™ platform, position the company favorably within a competitive market for neurological and metabolic therapies. In October 2026, TriGemX Bio raised USD 94 million in venture funding co-led by TCG Crossover Management, Viking Global Investors, and The Column Group. The company plans to use its proceeds from October 2026 funding to advance Phase 3 clinical trials of elismetrep for the treatment of migraine and support its ongoing development program.

## Funding rounds

- Series D, Feb 15, 2022, $236M — Polaris Partners, Alexandria Venture Investments, Parkwood Corporation, The Column Group, StepStone Group, Two Sigma Investments, Lux Capital, Casdin Capital, DNS Capital, Tao Capital Partners, Illumina Ventures, Mubadala Capital, Euclidean Capital, Hartford HealthCare Corporation
- Series C, Mar 20, 2020, $112M — Greenspring Associates, Polaris Partners, Alexandria Venture Investments, The Column Group, Two Sigma Investments, Lux Capital, Casdin Capital, Illumina Ventures, Euclidean Capital
- Series B, Dec 5, 2018, $21M — Polaris Partners, Alexandria Venture Investments, The Column Group, Two Sigma Investments, Lux Capital, Euclidean Capital, Illumina Ventures
- Series B, Feb 22, 2018, $66M — Polaris Partners, Alexandria Venture Investments, The Column Group, Two Sigma Investments, Lux Capital, Euclidean Capital, Illumina Ventures
- Series A, Oct 27, 2016, $16M — Polaris Partners, Alexandria Venture Investments, The Column Group, Lux Capital, Illumina Ventures
- Series A, Sep 30, 2015, $12M — Polaris Partners, Alexandria Venture Investments, The Column Group, Lux Capital, Illumina Ventures

## Investors

- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B, Series C, Series D
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A, Series B, Series C, Series D
- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series A, Series B, Series C, Series D
- Lux Capital (https://capitalatlas.ai/funds/lux-capital) — Series A, Series B, Series C, Series D
- Illumina Ventures (https://capitalatlas.ai/funds/illumina-ventures) — Series A, Series B, Series C, Series D
- Two Sigma Investments (https://capitalatlas.ai/funds/two-sigma-investments) — Series B, Series C, Series D
- Euclidean Capital — Series B, Series C, Series D
- Greenspring Associates (https://capitalatlas.ai/funds/greenspring-associates) — Series C
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series C, Series D
- Parkwood Corporation — Series D
- StepStone Group — Series D
- DNS Capital (https://capitalatlas.ai/funds/dns-capital) — Series D
- Tao Capital Partners (https://capitalatlas.ai/funds/tao-capital-partners) — Series D
- Mubadala Capital (https://capitalatlas.ai/funds/mubadala-capital) — Series D
- Hartford HealthCare Corporation — Series D